Anuncio
relacionado con: Regeneron PharmaceuticalsLearn about our homegrown technologies and novel approaches to drug discovery. At Regeneron, we don’t shy away from a scientific challenge.
- Science & Technology
See Regeneron's New Technology
Turning Science into Medicine
- About Regeneron
Industry-Leading Biotechnology
Reinventing Drug Discovery
- Antibodies at Work
End-to-End Research & Development
See Regeneron's Approved Medicines
- Genetic Research
Speeding Drug Discovery
Learn about the RGC
- Science & Technology
Resultado de búsqueda
Regeneron is a biotech company that develops new medicines for serious diseases, such as cancer, asthma and COVID-19. Learn about their scientific breakthroughs, clinical trials, responsibility goals and career opportunities.
Regeneron invierte en la ciencia y la tecnología para crear tratamientos que resuelven los misterios más complejos del cuerpo humano. Conozca su misión, sus innovaciones, sus responsabilidades corporativas y sus oportunidades profesionales.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous approved treatments and product candidates in development, most of ...
Regeneron is a biotech company that invents and develops medicines for serious diseases, such as eye, allergic, inflammatory, cancer, and rare diseases. Founded and led by physician-scientists, Regeneron uses proprietary technologies and genetics sequencing to create life-transforming treatments.
Regeneron developed a combination of monoclonal antibodies to treat COVID-19, which received emergency use authorization in 2020. The company also has ongoing research on new and existing variants, and collaborates with BARDA and Roche.
30 de jul. de 2021 · Regeneron announces FDA expanded authorization of REGEN-COV™, a COVID-19 antibody cocktail, for post-exposure prophylaxis in certain high-risk people. REGEN-COV is the only antibody therapy available for both treatment and prevention of COVID-19 in the U.S.
